NCT07288112 2026-02-23
DOC1021 Dendritic Cell Immunotherapy for Refractory Melanoma
Diakonos Oncology Corporation
Phase 1/2 Recruiting
Clinical Trials
4 trialsNCT02328755 2021-10-06
Peginterferon Alfa-2a to Enhance Anti-leukemic Responses After Allogeneic Transplantation in Acute Myeloid Leukemia
University of Michigan Rogel Cancer Center
Phase 1/2 Completed
NCT00423397 2013-12-19
Gefitinib and PEG-Interferon Alfa-2a in Treating Patients With Unresectable or Metastatic Skin Cancer
National Cancer Institute (NCI)
Phase 1/2 Unknown
NCT00962715 2012-08-03
Reactogenicity, Immunogenicity of Trivalent Influenza Vaccine With Recombinant Interferon Alpha Among Chronic Lymphocytic Leukemia
M.D. Anderson Cancer Center
Phase 1/2 Withdrawn